Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia

• DOI: 10.1007/s00277-020-04163-7
• Publication Date: 2020-07-03T14:03:34Z
• Authors: Desiree Kunadt; Christian Dransfeld; Claudia Dill; Maria Schmiedgen; Michael Kramer; Heidi Altmann; Christoph Röllig; Martin Bornhäuser; Ulrich Mahlknecht; Markus Schaich; Friedrich Stölzel
• Keywords: SNP; Hematology

Abstract Resistant disease is still a main obstacle in acute myeloid leukemia (AML) treatment. Therefore, individual genetic variations affecting therapy response are gaining increasing importance. Both SNPs and ABC transporter genes could already be associated with drug resistance. Here, we report allelic variants of MRP1 ( ABCC1 ) rs129081, rs212090, rs212091 significant influences on survival AML patients. DNA was extracted from bone marrow samples n = 160) at diagnosis. Genotyping 48 within seven different using real-time PCR revealed rs129081 GG variant higher OS p 0.035) DFS 0.01). Comparing TT AA rs212090 showed 0.021). SNP expression worse 0.006) difference between alleles 0.018). The multivariable models confirmed influence for (AA HR 0.296, 95% CI 0.113–0.774, 0.013 0.044). Rs129081 CG, AA, AG demonstrated impact 0.024, 0.029, 0.017, 0.042, respectively). This analysis demonstrates AML. As they were not to prognostic characteristics, suggest these independent markers